According to a new report from The BMJ, researchers who were testing Pfizer’s vaccine at several research facilities say speed may have come at the cost of data integrity and patient safety.
Regional director, Brook Jackson, who was employed at one research facility, Ventavia Research Group, has told The BMJ that the company falsified data, unblinded patients, and was slow to follow up on adverse events.
After repeatedly expressing these concerns to the research facility, Jackson emailed a complaint to the US Food and Drug Administration (FDA). The company fired Jackson the same day. Jackson provided The BMJ with all of the damning internal company documents.
During a recording of a meeting in late September 2020, a Ventavia executive can be heard saying that the company wasn’t able to quantify the types and number of errors they found when examining trial paperwork for quality control.
“In my mind, it’s something new every day,” a Ventavia executive says. “We know that it’s significant.”
According to the report, one executive identified three site staff members with whom to “Go over e-diary issue/falsifying data, etc.” One of them was “verbally counseled for changing data and not noting late entry,” a note indicates.
The first-quarter results published by Pfizer show its coronavirus jab has racked up billions for the biopharma giant in the first three months of 2021.
According to Reuters, the latest financial results reveal that Pfizer has vastly exceeded its Covid-19 vaccine sales forecast of $15bn, and now expects the jab to bring in over $60bn of revenue.
The CEO of Pfizer, Albert Bourla, when asked about when he foresaw the end of the pandemic, said that he does not see life going back to normal without regular vaccinations.
Israel has among the world’s highest levels of vaccination for COVID-19, with 80% of those 12 and older fully vaccinated, the vast majority with the Pfizer vaccine. Yet, the country is now recording one of the world’s highest infection rates and it’s recommended that Americans forgo travel to the country.
More than half of the cases in Israel, and over 60% of the hospitalizations for severe COVID cases are in fully vaccinated people. In Israel, citizens are not considered fully vaccinated unless they’ve had booster shots, and recently CDC director Rochelle Walensky hinted the same might be coming for the US.
According to the latest worldwide data, Singapore is now the most vaccinated country in the world, yet according to a recent story from The Guardian, Singapore hospitals are currently at risk of being ‘overwhelmed’ after a record number of daily Covid deaths.
A recent scientific paper published in Nature offers one of the most comprehensive estimates of the number of Americans infected with COVID-19 by the end of 2020 at more than 100 million people. That’s equal to almost one-third of the U.S. population.
If this estimate is accurate, it is safe to assume that the more transmissible delta variant which became dominant this year, may have already infected around 100 million more Americans in 2021.
This would mean that almost 75% of the population already have a natural immunity to the virus, not counting those who were vaccinated. The numbers would also mean that the overall infection fatality rate is far lower than previously believed.
Two COVID-19 antiviral pills are now very close to becoming available and are bringing claims by the national and international media that a ‘proven oral treatment’ will soon be available to quell the SARS-CoV-2 infection.
Pfizer’s PF-07321332, in combination with the HIV antiviral ritonavir, is well into Phase 3 testing as a treatment for people who are infected with SARS-CoV-2, but who are less likely to be hospitalized with COVID-19.
According to the New York Times, a five-day course of molnupiravir will cost about $700 per patient. Merck said that it expects to make 10 million treatment courses by the end of 2021, with more doses to be produced in 2022. The first few million treatments will rack up billions for the partnership duo.